A Novo Nordisk A/S investor says the pharmaceutical company’s failure to disclose how it tested experimental obesity shot ...
LOS ANGELES, CA / ACCESS Newswire / January 29, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...
On Friday, however, Novo Nordisk announced top-line results in yet another trial. While the results don't initially sound as ...
The readout comes on the heels of CagriSema’s disappointing Phase III performance, where it missed Novo’s projection of 25% ...
In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20 percent of their body weight, on average, a result that caused the Danish ...
About Robbins LLP : A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LL have been dedicated to helping shareholders recover losses, improve corporate governance ...
The Allegations: Rosen Law Firm is Investigating the Allegations that Novo Nordisk A/S (NYSE: NVO) Misled Investors Regarding its Business Operations.
Novo Nordisk is “well placed” to continue to benefit from the high demand for GLP-1 medications in the near-term, and while the CagriSema Phase 3 data in obesity was disappointing, it is still ...
The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.
On Dec. 20, Novo announced results from a phase 3 clinical trial surrounding one of its new GLP-1 candidates, called CagriSema. The name CagriSema is simply an amalgamation of the two primary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback